Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural ...

The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...

AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to ...

DIANT Pharma Signs Collaborative Accord to Strengthen U.S. Pharmaceutical Manufacturing DIANT is proud to stand alongside forward-thinking leaders who recognize the urgent need to modernize and secure ...

Seeing the Health Care sector get hit today wasn’t too surprising with the news that there is a potential for drug prices to ...

The new board will work with Abzena's scientific and commercial leadership to provide strategic guidance and insights.

Bayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the biotech was taken over by Eli Lilly in an $ ... is in phase I/II testing as a rescue therapy ...

Already developing a trio of incretin drugs for obesity, Eli Lilly has its sights set on a ... a monoclonal antibody that binds to the activin type II receptor on skeletal muscle and was ...